Published in Cancer Weekly, January 5th, 2010
Current imaging modalities miss up to 30% of breast cancers and cannot distinguish malignant tumors from benign tumors, thus requiring invasive biopsies. Approximately 5.6 million biopsies performed in the United States find only benign lesions. These biopsies cause substantial stress for the patients and have significantly high costs.
"The challenge has been to develop an imaging agent that will target a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-01-05)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.